

## TheraVet announces the signing of a research contract with Degroof Petercam

Gosselies (Wallonia, Belgium), November 9, 2021 - 7:30am CET - TheraVet (ISIN: BE0974387194 - ticker: ALVET), a pioneering company in the management of osteoarticular diseases in companion animals, announces today, **the signing of a research contract with Degroof Petercam.**

Banque Degroof-Petercam will initiate coverage of the Company through its sponsored research program, and support the Company in investors networking with roadshows and conferences through its corporate access services.

### About TheraVet SA

TheraVet is a veterinary biotechnology company specialising in osteoarticular treatments for animals. The Company develops targeted, safe and effective treatments to improve the quality of life of pets suffering from osteoarticular diseases. For pet owners, the health of their pets is a major concern and TheraVet's mission is to address the need for innovative and curative treatments. TheraVet works closely with international opinion leaders in order to provide a more effective response to ever-growing needs in the field of veterinary medicine. TheraVet is listed on Euronext Growth® Paris et Brussels, its head office is in Gosselies, Belgium, and it has a subsidiary in the US.

For more information, visit [www.thera.vet](http://www.thera.vet)

### Contacts

#### TheraVet

Sabrina Ena  
Chief Operating Officer  
[sabrina.ena@thera.vet](mailto:sabrina.ena@thera.vet)

Julie Winand  
Chief Corporate Officer  
[julie.winand@thera.vet](mailto:julie.winand@thera.vet)

#### NewCap

Investor Relations and Financial Communications  
Louis Tilquin / Olivier Bricaud  
[theravet@newcap.eu](mailto:theravet@newcap.eu)  
Tel: +33 (0)1 44 71 94 94

Press Relations  
Arthur Rouillé / Ambre Delval  
[theravet@newcap.eu](mailto:theravet@newcap.eu)  
Tel: +33 (0)1 44 71 00 15